Anbio Biotechnology (NNNN) | Stock Overview & Key Data
Anbio Biotechnology Performance Comparison
Stock Range
Today's Range
Low: $41.46
High: $47.23
on July 30, 2025
52 Week Range
Low: $5.18
High: $55.65
on February 19, 2025
on July 15, 2025
All-Time High: $55.65 on July 15, 2025
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$2.2B
EPS
0.06
P/E Ratio (TTM)
847.17
Forward P/E
N/A
P/B Ratio
124.89
PEG Ratio
N/A
Div. Yield
N/A
ROE
14.83%
Beta
N/A
Debt to Equity
0.00
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
-68.64%
Profit Margin
28.99%
Returns and Earnings
Return on Assets (TTM)
7.18%
Return on Equity (TTM)
14.83%
EBITDA
$2.4M
Net Income (TTM)
$2.4M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$0.19
Quarterly Revenue Growth (YoY)
-36.10%
Quarterly Earnings Growth (YoY)
N/A
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Anbio Biotechnology NNNN | 2.23B Mid-cap | -5.02% | 32.66% | 588.52% | 627.90% | 627.90% | 627.90% | 627.90% | 627.90% |
| Intuitive Surgical ISRG | 177.07B Large-cap | -0.29% | -7.89% | -2.96% | -13.73% | -4.49% | 11.29% | 108.27% | 118.93% |
| Becton, Dickinson BDX | 52.43B Large-cap | -0.57% | 5.39% | -12.34% | -26.94% | -19.85% | -24.94% | -28.59% | -27.43% |
| Avantor AVTR | 9.55B Mid-cap | 1.47% | 2.53% | 6.24% | -37.89% | -34.91% | -46.09% | -51.66% | -36.32% |
| Repligen RGEN | 7.04B Mid-cap | 4.88% | -1.23% | -10.97% | -26.67% | -14.12% | -24.01% | -50.12% | -19.58% |
| Stevanato STVN | 6.81B Mid-cap | -1.85% | 2.09% | 19.56% | 13.73% | 11.44% | 29.83% | 36.51% | 26.79% |
Ownership & Short Interest
Insider Ownership
4.78%
Institutional Ownership
4.94%
Shares Short
175K
Short Ratio
0.74
Short % of Shares Outstanding
0.40%
Average 10-Day Volume
141K
Average 90-Day Volume
201K
Anbio Biotechnology Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Anbio Biotechnology would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is NNNN's 52-week high and low?
- In the last 52 weeks, Anbio Biotechnology reached a high of $55.65 (on July 15, 2025) and a low of $5.18 (on February 19, 2025).
- What is the market cap and P/E ratio for NNNN?
- Curious about Anbio Biotechnology's size and valuation? Its market capitalization stands at 2.23B. When it comes to valuation, the P/E ratio (trailing twelve months) is 847.17, and the forward P/E (looking ahead) is N/A.
- Does NNNN pay dividends? If so, what's the yield?
- As for dividends, Anbio Biotechnology isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Anbio Biotechnology's main competitors or similar companies to consider before investing?
When looking at Anbio Biotechnology, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Intuitive Surgical
ISRG177.07B Healthcare Medical Instruments & Supplies 11.29% 108.27% Becton, Dickinson
BDX52.43B Healthcare Medical Instruments & Supplies -24.94% -28.59% Avantor
AVTR9.55B Healthcare Medical Instruments & Supplies -46.09% -51.66% Repligen
RGEN7.04B Healthcare Medical Instruments & Supplies -24.01% -50.12% Stevanato
STVN6.81B Healthcare Medical Instruments & Supplies 29.83% 36.51% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Anbio Biotechnology Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Anbio Biotechnology's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 14.83%, the Debt to Equity ratio from the most recent quarter is 0.00, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for NNNN?
- Looking at Anbio Biotechnology's growth, its revenue over the trailing twelve months (TTM) was $8M. Compared to the same quarter last year (YoY), quarterly revenue grew by -36.10%, and quarterly earnings saw a YoY growth of N/A.
- How much of NNNN stock is held by insiders and institutions?
- Wondering who owns Anbio Biotechnology stock? Company insiders (like executives and directors) hold about 4.78% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 4.94%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.